Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive

Executive Summary

Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive
Advertisement

Related Content

Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Amgen Projects Neulasta Sales Driven By Prescribing Growth, Not Switches
Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study
Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution
Raptiva Labeling Should Require Monitoring For Thrombocytopenia – Cmte.
Raptiva Manufacturing Issues Will Not Delay Approval, Launch – Genentech
Genentech/Xoma Raptiva Promotions Likely To Focus On Dosing Convenience
Biogen Amevive Revival Strategy Includes Shorter Time To Reimbursement
Biogen Amevive Revival Strategy Includes Shorter Time To Reimbursement
Advertisement
UsernamePublicRestriction

Register

PS042740

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel